emocha was established in 2014, with the goal of ending the deadly consequences of nonadherence. Since then, emocha has developed a turnkey service to improve medication adherence globally. The service is used across public health efforts, clinical trials, and managed care organizations to improve adherence and engage patients in care. emocha’s Video Directly Observed Therapy (VDOT) platform is an asynchronous platform designed to complement traditional Directly Observed Therapy (DOT) by reducing the burden of in person therapy for patients and providers.
How it works
Patients can upload videos of themselves taking their medication, and receive messages from providers through the app. Patients record each dose they take and upload the video with their smartphone. The system’s asynchronous capacity allows videos to be automatically uploaded whenever a patient has an internet connection. Similarly, messages from their provider will be received when connection is restored. If patients have any questions about their treatment, they can reach providers via the two way chat function included in the app.
emocha has been scored below according to it’s ability to serve the TB market for low- and middle-income countries (LMICs) along Fit for Purpose and Technical Specifications metrics. Note that higher scores equate to a greater ability to serve the market. For example, if a product scores well in the Provider Burden subcategory, that means that the burden for the provider is low.
For full descriptions of the sub-categories, see the 2021 DAT Market Landscape.
Fit for Purpose
Barriers to Entry100%
- Fairly low provider/system burden
- Highly portable and usable in high stigma areas (assuming patients are comfortable recording themselves)
- Intuitive for people accustomed to utilizing a smart phone
- Smart phone and semi-regular internet connection required